Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol

JULIAN KENYON, WAI LIU and ANGUS DALGLEISH
Anticancer Research October 2018, 38 (10) 5831-5835; DOI: https://doi.org/10.21873/anticanres.12924
JULIAN KENYON
1The Old Brewery, Winchester Hants, U.K.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jnkenyon@doveclinic.com
WAI LIU
2St George's University of London, London, U.K.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANGUS DALGLEISH
2St George's University of London, London, U.K.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Patient with ependymoma. A) A scan on the 6th of Jan 2016 showed enlargement of the posterior fossa mass. There were some, particularly multimodal features of radionecrosis, but in the context of a previously rapidly progressive tumour, an element of disease progression was also being considered. B) A subsequent scan on the 13th April 2016 showed further tumour progression and development of moderately severe supratentorial hydrocephalus. C) On the 30 Sept 2016, scans showed substantial improvement/reduction in size of the residual disease. There had been a substantial improvement in appearances, with marked reduction in size of the posterior fossa tumour from 3.4×3.2 cm in the sagittal plane to 1.7×1.7 cm. D) Scans performed on the 14th Dec 2016, showed a slow improvement; with impressive resolution of left CPA recurrent ependymoma.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Patient with tanycytic ependymoma. A) A scan on the 13th Jan 2017 showed a reduction in the size and enhancement of the left periventricular tumour. There was almost complete resolution of the parenchymal enhancement with a couple of small ependymal nodules remaining, but slightly smaller. There was no significant change in the T2/FLAIR appearance with Wallarian degeneration extending into the corticospinal tracts. B) A follow-up scan performed on the 21 Feb 2018 revealed evidence of disease progression with a near doubling of the enhancing soft tissue arising from the ependymal surface of the left lateral ventricle and projecting into the body of the left lateral ventricle. There are new enhancing foci in the left putamen and subthalamic region with further non-enhancing T2 hyperintense tumour expanding inferiorly into the left cerebral peduncle.

Tables

  • Figures
  • Table I.
  • Table II.
PreviousNext
Back to top

In this issue

Anticancer Research: 38 (10)
Anticancer Research
Vol. 38, Issue 10
October 2018
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 5 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol
JULIAN KENYON, WAI LIU, ANGUS DALGLEISH
Anticancer Research Oct 2018, 38 (10) 5831-5835; DOI: 10.21873/anticanres.12924

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol
JULIAN KENYON, WAI LIU, ANGUS DALGLEISH
Anticancer Research Oct 2018, 38 (10) 5831-5835; DOI: 10.21873/anticanres.12924
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Case Presentations
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Multi-Omic Analysis Reveals Disruption of Cholesterol Homeostasis by Cannabidiol in Human Cell Lines
  • Management of Concomitant Abdominal Aortic Aneurysm and Intra-abdominal, Retroperitoneal Malignancy
  • Concomitant Treatment of Malignant Brain Tumours With CBD - A Case Series and Review of the Literature
  • Google Scholar

More in this TOC Section

  • Role of 1p/19q Codeletion in Diffuse Low-grade Glioma Tumour Prognosis
  • Identification of Patients With Glioblastoma Who May Benefit from Hypofractionated Radiotherapy
  • Optimal Treatment of Hormone Receptor-positive Advanced Breast Cancer Patients With Palbociclib
Show more Clinical Studies

Similar Articles

Keywords

  • Cancer
  • cannabinoids
  • ependymoma
  • Prostate cancer
  • Breast cancer
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire